Business
Oncolytics Biotech® to Present Phase 2 Triple-Negative Breast Cancer Trial Update at the 2021 San Antonio Breast Cancer Symposium
Oncolytics Biotech® to Present Phase 2 Triple-Negative Breast Cancer Trial Update at...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"\n \n \n \n Oncolytics Biotech® to Present Phase 2 Triple-Negative Breast Cancer Trial Update at the 2021 San Antonio Breast Cancer Symposium\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen2{\nBORDER-TOP:1pt; BORDER-RIGHT:1pt; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM:1pt; PADDING-LEFT:0.50em; BORDER-LEFT:1pt; PADDING-RIGHT:0.50em\n}\n.prntblns{\nBORDER-TOP: 1pt; BORDER-RIGHT: 1pt; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt\n}\n.prntal{\nTEXT-ALIGN: LEFT\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n \n IRENE\n \n study is evaluating pelareorep-anti-PD-1 combination treatment in metastatic TNBC\n \n \n \n \n SAN DIEGO\n \n and\n \n CALGARY, AB\n \n ,\n \n Nov. 19, 2021\n \n /CNW/ -- Oncolytics Biotech\n \n ®\n \n Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Company will present an update on the Phase 2 IRENE trial in a poster at the 2021 San Antonio Breast Cancer Symposium (SABCS), which is taking place\n \n December 7\n \n – 10, 2021, both virtually and in-person, at the Henry B. González Convention Center in\n \n San Antonio, Texas\n \n .\n \n \n \n \n \n Details on the poster and its corresponding abstract, available on the\n \n SABCS website\n \n , are shown below.\n \n \n \n Program Number:\n \n OT2-25-01\n \n \n Title:\n \n \n IRENE\n \n study: Phase 2 study of INCMGA00012 and the oncolytic virus pelareorep in metastatic triple negative breast cancer\n \n \n Session Name:\n \n Ongoing Trials Poster Session 2\n \n \n Session Date:\n \n December 9, 2021\n \n \n Session Time:\n \n \n 5:00 PM\n \n –\n \n 6:30 PM CT\n \n /\n \n 6:00 PM\n \n –\n \n 7:30 PM ET\n \n \n \n Presenter:\n \n Dr.\n \n Mridula George\n \n \n \n \n About\n \n IRENE\n \n \n \n \n The\n \n IRENE\n \n (INCMGA00012 and the oncolytic virus pelareorep in metastatic triple-negative breast cancer) study is a single-arm, open-label, phase 2 study evaluating the combination of pelareorep and Incyte's anti-PD-1 checkpoint inhibitor retifanlimab (INCMGA00012) for the treatment of unresectable locally advanced or metastatic triple-negat...